PROFILE: Getting to know GSK dermatologist David Rubenstein, head to toe
This article was originally published in Scrip
Dr David Rubenstein, a dermatologist and the current vice-president of discovery and preclinical development at GlaxoSmithKline's skin health treatment and research company, Stiefel, believes pharma has only gotten skin deep when it comes to dermatology drug development.
You may also be interested in...
A complete response letter from the FDA in June knocked Intercept’s stock price down to 2014 levels, but perhaps the regulator is sending wider messages about NASH.
A selection of features you might have missed from the first six months of 2020, covering key topics from COVID-19 strategies in medtech to an analysis of pipeline focus areas across the pharma sector. Click on each section to get the full story behind the data.
The two-part vaccine becomes the second against Ebola to get approval. Janssen is now collaborating with the World Health Organization on vaccine pre-qualification to get it to people in need.